Evidence map›Paper›PMID 34337411›Full record

ArticleNeuro-oncology advances

Phase II trial of proton therapy versus photon IMRT for GBM: secondary analysis comparison of progression-free survival between RANO versus clinical assessment.

Karine A Al Feghali, James W Randall, Diane D Liu, Jeffrey S Wefel, Paul D Brown, David R Grosshans, Sarah A McAvoy, Maguy A Farhat, Jing Li, Susan L McGovern and 13 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neuro-oncology advances. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 4 institutions in 1 country.

Karine A Al FeghaliDepartment of Radiation Oncology, MD Anderson Cancer Center, Houston, Texas, USA.ORCID https://orcid.org/0000-0002-5538-1336
James W RandallDepartment of Radiation Oncology, MD Anderson Cancer Center, Houston, Texas, USA.
Diane D LiuDepartment of Biostatistics, MD Anderson Cancer Center, Houston, Texas, USA.
Jeffrey S WefelDepartment of Radiation Oncology, MD Anderson Cancer Center, Houston, Texas, USA.ORCID https://orcid.org/0000-0003-3584-023X
Paul D BrownDepartment of Radiation Oncology, Mayo Clinic, Rochester, Minnesota, USA.
David R GrosshansDepartment of Radiation Oncology, MD Anderson Cancer Center, Houston, Texas, USA.
Sarah A McAvoyDepartment of Radiation Oncology, University of Maryland, Baltimore, Maryland, USA.
Maguy A FarhatDepartment of Radiation Oncology, MD Anderson Cancer Center, Houston, Texas, USA.
Jing LiDepartment of Radiation Oncology, MD Anderson Cancer Center, Houston, Texas, USA.
Susan L McGovernDepartment of Radiation Oncology, MD Anderson Cancer Center, Houston, Texas, USA.
Mary F McAleerDepartment of Radiation Oncology, MD Anderson Cancer Center, Houston, Texas, USA.
Amol J GhiaDepartment of Radiation Oncology, MD Anderson Cancer Center, Houston, Texas, USA.
Arnold C PaulinoDepartment of Radiation Oncology, MD Anderson Cancer Center, Houston, Texas, USA.
Erik P SulmanDepartment of Radiation Oncology, NYU Langone, New York, New York, USA.
Marta Penas-PradoDepartment of Neuro-Oncology, National Institutes of Health, Bethesda, Maryland, USA.
Jihong WangDepartment of Radiation Oncology, MD Anderson Cancer Center, Houston, Texas, USA.
John de GrootDepartment of Neuro-Oncology, MD Anderson Cancer Center, Houston, Texas, USA.
Amy B HeimbergerDepartment of Radiation Oncology, MD Anderson Cancer Center, Houston, Texas, USA.
Terri S ArmstrongDepartment of Neuro-Oncology, National Institutes of Health, Bethesda, Maryland, USA.ORCID https://orcid.org/0000-0002-2414-0492
Mark R GilbertDepartment of Neuro-Oncology, National Institutes of Health, Bethesda, Maryland, USA.
Anita MahajanDepartment of Radiation Oncology, Mayo Clinic, Rochester, Minnesota, USA.
Nandita Guha-ThakurtaDepartment of Neuroradiology, MD Anderson Cancer Center, Houston, Texas, USA.
Caroline ChungDepartment of Radiation Oncology, MD Anderson Cancer Center, Houston, Texas, USA.
The University of Texas MD Anderson Cancer Center · USNational Institutes of Health · USMayo Clinic · USUniversity of Maryland, Baltimore · US

Funding

Fellow and Resident Radiation Oncology iNtensive Training in Imaging and Informatics to Empower Research Careers (FRONTI2ER)R25EB025787 · NIBIB · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI DAS, PRAJNAN, FULLER, CLIFTON DAVID · 2018 to 2022
$535k
NIBIB NIH HHS R25 EB025787
6 · The paper itself

Abstract

backgroundThis secondary image analysis of a randomized trial of proton radiotherapy (PT) versus photon intensity-modulated radiotherapy (IMRT) compares tumor progression based on clinical radiological assessment versus Response Assessment in Neuro-Oncology (RANO).

methodsEligible patients were enrolled in the randomized trial and had MR imaging at baseline and follow-up beyond 12 weeks from completion of radiotherapy. "Clinical progression" was based on a clinical radiology report of progression and/or change in treatment for progression.

resultsOf 90 enrolled patients, 66 were evaluable. Median clinical progression-free survival (PFS) was 10.8 (range: 9.4-14.7) months; 10.8 months IMRT versus 11.2 months PT (

conclusionsBased on this secondary analysis of a trial of PT versus IMRT for glioblastoma, while no difference in PFS was noted relative to treatment technique, RANO criteria identified progression more often and earlier than clinical assessment. This highlights the disconnect between measures of tumor response in clinical trials versus clinical practice. With growing efforts to utilize real-world data and personalized treatment with timely adaptation, there is a growing need to improve the consistency of determining tumor progression within clinical trials and clinical practice.

Indexed as

glioblastomaimaging endpointsprogression-free survivalradiation therapyRANO

Identifiers

PMID34337411
PMCPMC8320688
OpenAlexW3166334915

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.